E
CARM

Ergoteles’s Carisma Therapeutics CARM Stock Holding History

Ergoteles’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,209
Closed -$63.5K – 1304
2022
Q4 		$63.5K Buy
+5,209
New +$54.7K ﹤0.01% 1271
2022
Q3 		– Sell
-49,480
Closed -$802K – 1580
2022
Q2 		$802K Buy
+49,480
New +$566K 0.02% 641

Other funds holding CARM

TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
Deuterium Capital Management Clearwater, Florida $86M AUM 87.31% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles's CARM Position: Q1 2023 in Review

Ergoteles sold out of Carisma Therapeutics (CARM) in Q1 2023, closing a stake of 5,209 shares — an estimated $63.5K sold.

Ergoteles first reported a position in CARM in Q2 2022 and held it in 2 quarters. The position peaked at $802K in Q2 2022. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2023.

  • Ergoteles reported no remaining Carisma Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 5,209 Carisma Therapeutics shares in Q1 2023, an estimated $63.5K.
  • Ergoteles first reported a position in Carisma Therapeutics in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Carisma Therapeutics position peaked at $802K in Q2 2022.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.